Literature DB >> 12406895

Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow.

Jeroen G Noordzij1, Nicole S Verkaik, Mirjam van der Burg, Lieneke R van Veelen, Sandra de Bruin-Versteeg, Wouter Wiegant, Jaak M J J Vossen, Corry M R Weemaes, Ronald de Groot, Malgorzata Z Zdzienicka, Dik C van Gent, Jacques J M van Dongen.   

Abstract

Severe combined immunodeficiency disease (SCID) can be immunologically classified by the absence or presence of T, B, and natural killer (NK) cells. About 30% of T(-)B(-)NK(+) SCID patients carry mutations in the recombination activating genes (RAG). Some T(-)B(-)NK(+) SCID patients without RAG gene mutations are sensitive to ionizing radiation, and several of these radiosensitive (RS) SCID patients were recently shown to have large deletions or truncation mutations in the Artemis gene, implying a role for Artemis in DNA double-strand break (dsb) repair. We identified 5 RS-SCID patients without RAG gene mutations, 4 of them with Artemis gene mutations. One patient had a large genomic deletion, but the other 3 patients carried simple missense mutations in conserved amino acid residues in the SNM1 homology domain of the Artemis protein. Extrachromosomal V(D)J recombination assays showed normal and precise signal joint formation, but inefficient coding joint formation in fibroblasts of these patients, which could be complemented by the wild-type Artemis gene. The cells containing the missense mutations in the SNM1 homology domain had the same recombination phenotype as the cells with the large deletion, indicating that these amino acid residues are indispensable for Artemis function. Immunogenotyping and immunophenotyping of bone marrow samples of 2 RS-SCID patients showed the absence of complete V(H)-J(H) gene rearrangements and consequently a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint-that is, at the transition from CyIgmu(-) pre-B-I cells to CyIgmu(+) pre-B-II cells. The completeness of this arrest illustrates the importance of Artemis at this stage of lymphoid differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406895     DOI: 10.1182/blood-2002-01-0187

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Autoinhibition of the Nuclease ARTEMIS Is Mediated by a Physical Interaction between Its Catalytic and C-terminal Domains.

Authors:  Doris Niewolik; Ingrid Peter; Carmen Butscher; Klaus Schwarz
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

2.  In silico identification and analysis of new Artemis/Artemis-like sequences from fungal and metazoan species.

Authors:  Diego Bonatto; Martin Brendel; João Antonio Pêgas Henriques
Journal:  Protein J       Date:  2005-08       Impact factor: 2.371

3.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

4.  A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation.

Authors:  Mirjam van der Burg; Lieneke R van Veelen; Nicole S Verkaik; Wouter W Wiegant; Nico G Hartwig; Barbara H Barendregt; Linda Brugmans; Anja Raams; Nicolaas G J Jaspers; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

5.  A hypomorphic Artemis human disease allele causes aberrant chromosomal rearrangements and tumorigenesis.

Authors:  Cheryl Jacobs; Ying Huang; Tehmina Masud; William Lu; Gerwin Westfield; William Giblin; JoAnn M Sekiguchi
Journal:  Hum Mol Genet       Date:  2010-12-08       Impact factor: 6.150

6.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

Authors:  Mirjam van der Burg; Hanna Ijspeert; Nicole S Verkaik; Tuba Turul; Wouter W Wiegant; Keiko Morotomi-Yano; Pierre-Olivier Mari; Ilhan Tezcan; David J Chen; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

7.  Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency.

Authors:  Kerstin Felgentreff; Yu Nee Lee; Francesco Frugoni; Likun Du; Mirjam van der Burg; Silvia Giliani; Ilhan Tezcan; Ismail Reisli; Ester Mejstrikova; Jean-Pierre de Villartay; Barry P Sleckman; John Manis; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2015-04-25       Impact factor: 10.793

8.  ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.

Authors:  Sarah A Maas; Nina M Donghia; Kathleen Tompkins; Oded Foreman; Kevin D Mills
Journal:  BMC Biol       Date:  2010-10-27       Impact factor: 7.431

9.  DNA double-strand break signaling and human disorders.

Authors:  Toshiyuki Bohgaki; Miyuki Bohgaki; Razqallah Hakem
Journal:  Genome Integr       Date:  2010-11-05

10.  Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase.

Authors:  Kiran N Mahajan; Beverly S Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.